Citations

Showing 10 of 108081 citations.

Precision Medicine—Right Treatment, Right Patient, Right Time, Wrong Approach?
Mills, John R.

Mayo Clinic

Clinical Chemistry | March 28, 2017 | Volume: 63 | Issue: 4 | Pages: 928-929

10.1373/clinchem.2016.267963 | PMID 28351859 Get It

Wnt/β‐Catenin Signaling Activates Expression of the Bone‐Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types
Vega, Oscar A., Lucero, Claudia, Araya, Héctor, Jerez, Sofía , Tapia, Julio C. , Antonelli, Marcelo , Salazar‐Onfray, Flavio , Heras, Facundo Las, Thaler, Roman , Riester, Scott M. , Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J, Galindo, Mario A , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Biochemistry | March 28, 2017 | Volume: 118 | Issue: 11 | Pages: 3662-3674

10.1002/jcb.26011 | PMID 28370561 Get It

ABSTRACTOsteosarcoma is the most common malignant bone tumor in children and adolescents. Metastasis and poor responsiveness to chemotherapy in osteosarcoma correlates with over‐expression of the runt‐related transcription factor RUNX2, which normally plays a key role in osteogenic lineage commitment, osteoblast differentiation, and bone formation. Furthermore, WNT/β‐catenin signaling is over‐activated in osteosarcoma and promotes tumor progression. Importantly, the WNT/β‐catenin pathway normally activates RUNX2 gene expression during osteogenic lineage commitment. Therefore, we examined whether the WNT/β‐catenin pathway controls the tumor‐related elevation of RUNX2 expression in osteosarcoma. We analyzed protein levels and nuclear localization of β‐catenin and RUNX2 in a panel of human osteosarcoma cell lines (SAOS, MG63, U2OS, HOS, G292, and 143B). In all six cell lines, β‐catenin and RUNX2 are expressed to different degrees and localized in the nucleus and/or cytoplasm. SAOS cells have the highest levels of RUNX2 protein that is localized in the nucleus, while MG63 cells have the lowest RUNX2 levels which is mostly localized in the cytoplasm. Levels of β‐catenin and RUNX2 protein are enhanced in HOS, G292, and 143B cells after treatment with the GSK3β inhibitor SB216763. Furthermore, small interfering RNA (siRNA)‐mediated depletion of β‐catenin inhibits RUNX2 expression in G292 cells. Thus, WNT/β‐catenin activation is required for RUNX2 expression in at least some osteosarcoma cell types, where RUNX2 is known to promote expression of metastasis related genes. J. Cell. Biochem. 118: 3662–3674, 2017. © 2017 Wiley Periodicals, Inc.
Ways to Write a Milestone: Approaches to Operationalizing the Development of Competence in Graduate Medical Education
Reed, Darcy A. , Starr, Stephanie R. , Havyer, Rachel D. , Lang, Tara R., Norby, Suzanne M. , Leep Hunderfund, Andrea N, Hunderfund, Andrea N. Leep

Mayo Clinic

Academic Medicine | March 28, 2017 | Volume: 92 | Issue: 9 | Pages: 1328-1334

10.1097/acm.0000000000001660 | PMID 28353504 Get It

Purpose To identify approaches to operationalizing the development of competence in Accreditation Council for Graduate Medical Education (ACGME) milestones. Method The authors reviewed all 25 “Milestone Project” documents available on the ACGME Web site on September 11, 2013, using an iterative process to identify approaches to operationalizing the development of competence in the milestones associated with each of 601 subcompetencies. Results Fifteen approaches were identified. Ten focused on attributes and activities of the learner, such as their ability to perform different, increasingly difficult tasks (304/601; 51%), perform a task better and faster (171/601; 45%), or perform a task more consistently (123/601; 20%). Two approaches focused on context, inferring competence from performing a task in increasingly difficult situations (236/601; 29%) or an expanding scope of engagement (169/601; 28%). Two used socially defined indicators of competence such as progression from “learning” to “teaching,” “leading,” or “role modeling” (271/601; 45%). One approach focused on the supervisor’s role, inferring competence from a decreasing need for supervision or assistance (151/601; 25%). Multiple approaches were often combined within a single set of milestones (mean 3.9, SD 1.6). Conclusions Initial ACGME milestones operationalize the development of competence in many ways. These findings offer insights into how physicians understand and assess the developmental progression of competence and an opportunity to consider how different approaches may affect the validity of milestone-based assessments. The results of this analysis can inform the work of educators developing or revising milestones, interpreting milestone data, or creating assessment tools to inform milestone-based performance measures.
Looking Under the Streetlight? A Framework for Differentiating Performance Measures by Level of Care in a Value-Based Payment Environment
Naessens, James M. , Such, Monica B. Van, Nesse, Robert E., Dilling, James A., Swensen, Stephen J., Thompson, Kristine M., Orlowski, Janis M., Santrach, Paula J., Such, Monica Van

Mayo Clinic

Academic Medicine | March 28, 2017 | Volume: 92 | Issue: 7 | Pages: 943-950

10.1097/acm.0000000000001654 | PMID 28353502 Get It

The majority of quality measures used to assess providers and hospitals are based on easily obtained data, focused on a few dimensions of quality, and developed mainly for primary/community care and population health. While this approach supports efforts focused on addressing the triple aim of health care, many current quality report cards and assessments do not reflect the breadth or complexity of many referral center practices. In this article, the authors highlight the differences between population health efforts and referral care and address issues related to value measurement and performance assessment. They discuss why measures may need to differ across the three levels of care (primary/community care, secondary care, complex care) and illustrate the need for further risk adjustment to eliminate referral bias. With continued movement toward value-based purchasing, performance measures and reimbursement schemes need to reflect the increased level of intensity required to provide complex care. The authors propose a framework to operationalize value measurement and payment for specialty care, and they make specific recommendations to improve performance measurement for complex patients. Implementing such a framework to differentiate performance measures by level of care involves coordinated efforts to change both policy and operational platforms. An essential component of this framework is a new model that defines the characteristics of patients who require complex care and standardizes metrics that incorporate those definitions.
A Novel Prosthetic Joint Infection Pathogen, Mycoplasma salivarium, Identified by Metagenomic Shotgun Sequencing
Thoendel, Matthew , Jeraldo, Patricio , Greenwood‐Quaintance, Kerryl E. , Steckelberg, James M., Osmon, Douglas R. , Patel, Robin , Chia, Nicholas , Abdel, Matthew P. , Jeraldo, Patricio R , Patel, Robin , Thoendel, Matthew J

Mayo Clinic

Clinical Infectious Diseases | March 28, 2017 | Volume: 65 | Issue: 2 | Pages: 332-335

10.1093/cid/cix296 | PMID 28379472 Get It

A Patient as Art: Andrew Wyeth’s Portrayal of Christina Olson’s Neurologic Disorder in Christina’s World
Patterson, Marc C. , Cole, Thomas B., Siegel, Eliot L. , Mackowiak, Philip A. , Patterson, Marc

Mayo Clinic

Journal of Child Neurology | March 28, 2017 | Volume: 32 | Issue: 7 | Pages: 647-649

10.1177/0883073817700603 | PMID 28349775 Get It

In Christina’s World, one of the most beloved works of American art, Andrew Wyeth painted Christina Olson crawling crablike across the field below her house, raised on emaciated arms, with a swollen knob for an elbow, and hands clenched and gnarled. The significance of these physical abnormalities, and the message Wyeth endeavored to convey via the portrait, are considered here in light of Christina’s medical history and the disorder it most likely signifies.
Radiologic-Pathologic Correlation: Acellular Dermal Matrix (Alloderm®) Used in Breast Reconstructive Surgery
Lee, Christine U. , Bobr, Aleh , Torres‐Mora, Jorge

Mayo Clinic

Journal of Clinical Imaging Science | March 28, 2017 | Volume: 7 | Issue: No issue available | Pages: 13

10.4103/jcis.jcis_7_17 | PMID 28515964 Get It

Acellular dermal matrix (ADM) such as Alloderm®is sometimes used in tissue reconstruction in primary and reconstructive breast surgeries. As ADM is incorporated into the native tissues, the evolving imaging findings that would correlate with varying degrees of host migration and neoangiogenesis into the matrix can be challenging to recognize. In the setting of a palpable or clinical area of concern after breast reconstructive surgery following breast cancer, confident diagnosis of a mass representing ADM rather than recurring or developing disease can be challenging. Such diagnostic imaging uncertainties generally result in short-term imaging and clinical follow-up, but occasionally, biopsy is performed for histopathological confirmation of benignity. A case of biopsy-proven Alloderm®is described. To the best of our knowledge, this is the first radiologic-pathologic correlation of ADM in the literature.
Intra-articular implantation of collagen scaffold carriers is safe in both native and arthrofibrotic rabbit knee joints
Walker, Justin A. , Ewald, Timothy J., Lewallen, Eric A. , Wijnen, André J. van , Hanssen, Arlen D. , Morrey, B.F. , Morrey, Mark E. , Abdel, Matthew P. , Sánchez‐Sotelo, Joaquín , van Wijnen, Andre J

Mayo Clinic

Bone & Joint Research | March 28, 2017 | Volume: 6 | Issue: 3 | Pages: 162-171

10.1302/2046-3758.63.bjr-2016-0193 | PMID 28347978 Get It

Objectives Sustained intra-articular delivery of pharmacological agents is an attractive modality but requires use of a safe carrier that would not induce cartilage damage or fibrosis. Collagen scaffolds are widely available and could be used intra-articularly, but no investigation has looked at the safety of collagen scaffolds within synovial joints. The aim of this study was to determine the safety of collagen scaffold implantation in a validated in vivo animal model of knee arthrofibrosis. Materials and Methods A total of 96 rabbits were randomly and equally assigned to four different groups: arthrotomy alone; arthrotomy and collagen scaffold placement; contracture surgery; and contracture surgery and collagen scaffold placement. Animals were killed in equal numbers at 72 hours, two weeks, eight weeks, and 24 weeks. Joint contracture was measured, and cartilage and synovial samples underwent histological analysis. Results Animals that underwent arthrotomy had equivalent joint contractures regardless of scaffold implantation (-13.9° versus -10.9°, equivalence limit 15°). Animals that underwent surgery to induce contracture did not demonstrate equivalent joint contractures with (41.8°) or without (53.9°) collagen scaffold implantation. Chondral damage occurred in similar rates with (11 of 48) and without (nine of 48) scaffold implantation. No significant difference in synovitis was noted between groups. Absorption of the collagen scaffold occurred within eight weeks in all animals Conclusion Our data suggest that intra-articular implantation of a collagen sponge does not induce synovitis or cartilage damage. Implantation in a native joint does not seem to induce contracture. Implantation of the collagen sponge in a rabbit knee model of contracture may decrease the severity of the contracture. Cite this article: J. A. Walker, T. J. Ewald, E. Lewallen, A. Van Wijnen, A. D. Hanssen, B. F. Morrey, M. E. Morrey, M. P. Abdel, J. Sanchez-Sotelo. Intra-articular implantation of collagen scaffold carriers is safe in both native and arthrofibrotic rabbit knee joints. Bone Joint Res 2016;6:162–171. DOI: 10.1302/2046-3758.63.BJR-2016-0193.
Alpha-1 antitrypsin dysfunction and large artery stroke
Meschia, James F.

Mayo Clinic

Proceedings of the National Academy of Sciences | March 27, 2017 | Volume: 114 | Issue: 14 | Pages: 3555-3557

10.1073/pnas.1702751114 | PMID 28348245 Get It

Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix
Heim, Joel B. , Squirewell, Edwin J., Neu, Ancilla, Zocher, Georg , Sominidi‐Damodaran, Sindhuja , Wyles, Saranya P. , Nikolova, Ekaterina , Behrendt, Nille, Saunte, Ditte Marie Lindhardt , Lock‐Andersen, Jørgen, Gaonkar, Krutika S. , Yan, Huihuang , Deursen, Jan van, Sprangers, Remco , Stehle, Thilo , Böttcher, Ralph T. , Lee, Jeong‐Heon , Ördög, Tamás , Meves, Alexander , van Deursen, Jan, Meves, Alexander , Sarkaria, Jann N. , Krendel, Mira , Lee, Jeong-Heon , Heim, Joel B

Mayo Clinic

Proceedings of the National Academy of Sciences | March 27, 2017 | Volume: 114 | Issue: 15 | Pages: 3933-3938

10.1073/pnas.1614894114 | PMID 28348210 Get It

Significance Focal adhesion kinase (FAK) is an intensely studied protein involved in many medically relevant biological processes, including cancer. Despite the large interest in FAK, a promising strategy to target FAK therapeutically is elusive. Here, we show that a region within the FAK protein that contains autophosphorylation site tyrosine (Y) 397 is essential for FAK activity in vivo. Myosin-1E (MYO1E), an actin-dependent molecular motor protein, directly interacts with FAK to induce Y397 autophosphorylation, which, in turn, causes changes in gene expression commonly observed in aggressive cancer. Our findings are significant because they further delineate FAK function in vivo and identify the MYO1E–FAK interaction as a possible Achilles’ heel for cancer.